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Renal fibrosis in mice treated with exogenous human recombi- able overlap between isoforms. For example TGF-b pro-
nant transforming growth factor-b2. tects tissues from ischemia-reperfusion injury by mod-
Background. The biologic responses to transforming growth lating the production and diverse activities of severalfactor-b (TGF-b) suggest many potential therapeutic applica-
vasoactive peptides [2–4], controlling the response oftions; however, in the only clinical trial to examine the effect
endothelial cells to injury [5], and stabilizing mitochon-of the systemic administration of a TGF-b isoform, patients
experienced significant but reversible declines in renal function. drial function [6]. TGF-bs are also potent immunosup-
We studied the effects of administering human recombinant pressants capable of inducing T-cell apoptosis [7], medi-
TGF-b2 to adult mice. ating antigen expression [8], regulating the developmentMethods. The effect of daily administration of TGF-b2 on
of antigen-presenting cells [9], and inhibiting the prolifer-tissue vasoconstriction, tissue levels of endothelin and angio-
ation of hematopoeitic progenitor cells [10]. The regula-tensin II, tissue hypoxia, and renal fibrosis were examined.
Results. Daily administration of TGF-b2 at 10 or 100 mg/kg tion of these varied activities is likely to find widespread
caused apparent tissue vasoconstriction that was visualized by therapeutic application in the treatment of autoimmune
vascular casting, with the largest impact seen in the kidney. diseases [11], ischemia-reperfusion injury [12], and organTissue levels of endothelin 1 and angiotensin II were signifi-
transplantation [13], as well as use as an adjunct to che-cantly elevated in kidneys of treated mice, as was urinary throm-
motherapy [14]. TGF-bs also play a central role in medi-boxane b2. Renal fibrosis was observed in the cortical tubular
interstitium and vasculature, particularly at the cortical-medul- ating the repair of damaged tissues, including skin, bone,
lary junction and medullary vasa recta; however, glomerular and muscle [15].
sclerosis was not observed. Fibrosis was correlated to focal Transforming growth factor-bs are also the principaltissue hypoxia as determined by immunohistochemical detec-
causative agent of pathologic scarring and fibrosis thattion of tissue bound pimondazole.
can, in extreme cases, lead to organ failure. Clearly, inConclusion. We conclude that there are significant histo-
pathologic consequences, focused in the kidney, resulting from these cases, neutralization of TGF-b activity would have
the daily administration of high doses of human recombinant therapeutic value [16]. The pathologic potential of TGF-b
TGF-b2, and we propose that selective vascular constriction underscores the critical importance of thoroughly defin-with consequent tissue hypoxia is a contributing factor.
ing parameters for delivery and dosage of these mole-
cules for therapeutic use. Identifying the potential toxic-
ity of these factors and whether these consequences areTransforming growth factor-b2 (TGF-b2) is a member
reversible would help to establish a therapeutic index inof the highly conserved TGF-b superfamily that includes
humans. The importance of such studies was emphasizednearly 40 multifunctional peptide growth factors. TGF-b2
by the only clinical trial to examine the effect of systemicis one of three mammalian isoforms that share 70 to 80%
administration of TGF-b2 in patients with chronic multi-sequence identity and affect their biologic activities through
ple sclerosis. These patients experienced significant butinteraction with a common set of serine/threonine kinase
reversible declines in renal function when dosed withreceptors [1]. Each TGF-b isoform elicits diverse bio-
TGF-b2 [17].logic responses, although these responses show consider-
As a step toward understanding the cellular and mo-
lecular basis of TGF-b toxicity, we have studied the
effects of administering human recombinant TGF-b2 toKey words: kidney fibrosis, hypoxia, transforming growth factor-b2,
vasoconstriction, ischemia, glomerular filtration rate. mice. Here, we present evidence that the daily adminis-
tration of high doses of TGF-b2 to normal, healthy miceReceived for publication January 13, 2000
causes profound vasoconstriction of renal vasculatureand in revised form May 2, 2000
Accepted for publication June 23, 2000 and promotes vascular fibrosis at sites of physiologic
tissue hypoxia.Ó 2000 by the International Society of Nephrology
2367
Ledbetter et al: Recombinant TGF-b2 in mice2368
METHODS or TGF-b2 dosed mice on the day following the final
dose. After 90 minutes, mice were prepared for immuno-Animals
histochemistry as described previously in this article. De-
ICR and C57/Bl male mice, six weeks of age, were tection of tissue-bound pimonidazole was carried out by
purchased from Taconic Farms (Germantown, NY, USA). employing a specific monoclonal antibody diluted 1:100
Mice were housed in animal facility with standard light followed by a peroxidase-conjugated secondary anti-
cycles and were fed standard mouse chow and tap water, body, as described previously in this article. Pimonida-
ad libitum. For urine collection, mice were housed for zole hydrochloride and its corresponding monoclonal
24 hours in appropriately sized Nalgene metabolism cages. antibody were kindly provided by Dr. James Raleigh
All studies were conducted in accordance with the NIH (University of North Carolina, Chapel Hill, NC, USA).
Guide for the Care and Use of Laboratory Animals.
Vascular casting
Protein formulation
Mice were placed into deep anesthesia, and the vascu-
Human recombinant TGF-b2 was produced at Gen- lar system was extensively perfused with heparinized
zyme Corp (Framingham, MA, USA). TGF-b2 was for- saline. A solution of white siliconized rubber (Microfil;
mulated for intraperitoneal injection in 20 mmol/L Na2PO4, Flowtech, Carver, MA, USA), prepared according to the
130 mmol/L NaCl, 15% (wt/wt) propylene glycol, 20% manufacturer’s instructions, was introduced into the left
(wt/wt) polyethylene glycol 400, and 1% ethanol. The ventricle at the rate of 0.5 mL/min using a Harvard sy-
pH was adjusted to 7.2, and this solution was stored at ringe pump (Harvard Apparatus, South Natick, MA,
48C for the duration of the study. The concentration and USA). A minimum of 8 mL was perfused into each
activity of formulated TGF-b2 were verified by quantita- mouse. Thereafter, the carcass remained at room tem-
tive enzyme-linked immunosorbent assay (ELISA) and perature for one hour, allowing for polymerization of the
bioassay, and the effect of storage conditions on these silicone rubber, followed by 24 hours at 48C, whereupon
parameters was negligible (E. Nichols, personal commu- organs of interest were removed and cleared by incuba-
nication). The injection volume was 200 mL. tion in a series of alcohol-methyl salicylate solutions, as
indicated by the manufacturer. Samples were stored and
Histology photographed in methyl salicylate.
For routine histologic examination, tissues were fixed
Biochemical measurementsovernight in 10% neutral-buffered formalin and were
prepared for paraffin embedding. Five micrometer sec- For the determination of tissue levels of endothelin-1,
tions were stained with hematoxylin and eosin or Mas- kidneys were finely minced and homogenized in 10 vol-
son’s trichrome for microscopic analysis. For immunohis- umes (g/mL) of 1 mol/L acetic acid containing 1 mg/mL
tochemistry, mice were overdosed with injectable sodium pepstatin A and a protease inhibitor cocktail (P8340;
pentabarbital, perfused with five blood volumes of hepa- Sigma) at 48C. Tissue homogenates were centrifuged at
rinized saline, perfused with freshly prepared 4% para- 100,000 3 g for 20 minutes at 48C, and the supernatants
formaldehyde and processed for light microscopy. Five were collected and stored at 2208. Endothelin-1 was
micrometer paraffin sections were deparaffinized, and extracted from tissue homogenates following the proto-
tissue sections were permeabilized by incubation with col of Wong and Jeng [18]. Briefly, C18 (Sep-Pak; Waters
Autozyme (Biomedia, Foster City, CA, USA) at 378C Corp., Milford, MA, USA) columns were pretreated
for 30 minutes. with two volumes of 90% acetonitrile in 0.1% trifluoace-
Antibodies against the propeptide and mature colla- tic acid (TFA) and two volumes of 25% acetonitrile in
gen types I and III were kindly provided by J. Madri 0.1% TFA. Tissue homogenate (0.2 mL) was adjusted
(Yale University, New Haven, CT, USA). Antibodies to contain a final concentration of 0.25% TFA and 25%
against perlecan, a basement membrane proteoglycan, acetonitrile and was applied to the column. Columns were
were kindly provided by J. Hassell (Shriner’s Institute, washed with six volumes of 25% acetonitrile in 0.1%
Tampa, FL, USA) and were used at a dilution of 1:100. TFA and then three volumes of H2O and three volumes
Antibodies against a-smooth muscle actin (a-SMA) were of 50% methanol. Endothelin-1 was eluted with five vol-
purchased from Sigma (St. Louis, MO, USA) and were umes of 50% methanol in 4% acetic acid. Eluate was
used according to the manufacturer’s instruction. Anti- lyophilized and resuspended in 1% TFA. Endothelin-1
body localization was detected using the avidin-biotin was quantitated by EIA (Cayman Chemical, Ann Arbor,
complex (ABC) peroxidase method (Vector Labora- MI, USA). Urinary thromboxane B2 (TXB2) was quanti-
tories, Burlingame, CA, USA). tated by enzyme immunoassay (EIA) (Cayman Chemi-
Visualization of tissue hypoxia was accomplished by cal); samples from 24-hour urine collection were diluted
injecting pimonidazole hydrochloride (60 mg/kg; pre- 1:10 for these determinations. Serum creatinine and uri-
nary N-acetylglucosamine were quantitated by spectro-pared in injectable water) into the tail vein of control
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photometric methods employing diagnostic reagents of gross intraorgan fibrosis, no glomerular sclerosis, and
no cellular infiltration seen in the kidneys of TGF-b2–purchased from Sigma and Boehringer Mannheim (Indi-
anapolis, IN, USA), respectively. Tissue levels of angio- treated mice (Fig. 1 A, D). Tubular epithelial cells were
largely normal in appearance, although cellular vacuolestensin II were determined following the methods of Fox
et al [19]. Kidneys were homogenized in 100% methanol were present. Furthermore, tubular protein casts were
not abundant. Urinary levels of N-acetylglucosaminidase,at 48C, lyophilized, and resuspended in EIA assay buffer
(Peninsula Laboratories, Belmont, CA, USA) and were a brush border enzyme elevated by tubular damage, were
unaffected by TGF-b2 dosing. There was, however, aapplied to a 2.8 mL pH phenylBond Elut Cartridge (Var-
ian, Palo Alto, CA, USA). Columns were pretreated modest reduction in the luminal space within the capil-
lary plexus located at the corticomedullary junction andwith one volume of methanol and then two volumes
of H2O. Following sample application, columns were the downstream vascular bed of the outer medullary (vasa
recta; Fig. 1 E, F). Highlighting connective tissue deposi-washed with one volume each of H2O, hexane and chlo-
roform and bound material eluted in 90% methanol. tion by staining tissue sections with trichrome showed
connective tissue buildup in the cortical intertubularEluted samples were lyophilized, resuspended in assay
buffer, and quantitated by EIA (Peninsula Labora- space but not in the glomeruli. Additional connective
tissue was also seen deposited adjacent to vascular struc-tories). Developed EIA plates were read on a Spectra
Max 340 plate reader, and data were analyzed with Soft- tures (interlobular and glomerular arterioles) in the cor-
tex (Fig. 1B) but was especially prominent in the capillarymaxPro (Molecular Devices, Sunnyvale, CA, USA). All
samples were run in duplicate. network of the inner and outer medulla (Fig. 1F). En-
hanced deposition of connective tissue proteins was
Statistical methods confirmed by immunohistochemical staining. Specific an-
tibodies against the procollagen peptide of type III colla-Values are reported as means 6 SD. One-way analysis
of variance (ANOVA) was performed with the aid of gen demonstrated increased staining in the cortical tubu-
lar interstitium (Fig. 2B) and in the vasa recta of theOrigon Ó (Microcal, Northampton, MA, USA). Statistical
outer medulla (Fig. 2D) This was comparable to thesignificance was defined as P , 0.05.
appearance of trichrome stained sections in Figure 1. In
contrast, normal renal tissue (Fig. 2 A, C) did not show
RESULTS increased staining. Similar, although less intense, staining
Male mice dosed daily, for four days, with 100 mg/kg was seen with antibodies directed against the propeptide
TGF-b2 had a 30% reduction in body weight (39 6 7 of type I collagen, whereas another extracellular matrix
vs. 27 6 3 g), were less mobile, and showed a core body component, perlecan, showed no increase (data not
temperature that was, on average, three degrees lower shown). Tissue sections were also stained with antisera
than the vehicle control group. This response depended against a-actin, which stained glomerular mesangial and
on the dosage and administration schedule; at lower arterial smooth muscle cells but did not recognize areas
doses (10 and 50 mg/kg) or dosing three times weekly, of tissue fibrosis (data not shown). This result suggested
there was little loss of weight or mobility. At autopsy, that the deposition of fibrotic tissue was not due to an
mice that received daily doses of 100 mg/kg TGF-b2 increase in the population of smooth muscle actin-posi-
exhibited a thickened, fibrous body wall that extended tive cells, for example myofibroblasts.
beyond the injection site. The walls of major abdominal Our early observation that TGF-b2–treated mice ap-
blood vessels and ureters were also visually thickened, peared ischemic prompted us to explore means of visual-
as was the mesothelial lining of the peritoneum. In some izing the vascular system. For this purpose, male mice
cases, adjacent organs were bridged with connective tis- were dosed with 10 or 100 mg/kg TGF-b2 daily for four
sue and, for that reason, were relatively immotile. Kidney days, and on the fifth day, the entire vascular system was
weight was reduced 30%, and the liver, although of nor- perfused with a solution of silicone rubber. As shown in
mal size, had a roughened and pebbled surface. Addi- Figure 3, the accessibility of the renal vascular system
tionally, spleen and adrenals were visually reduced in to the silicone perfusate was markedly diminished in
size. Several visceral organs and especially the kidney mice treated with either dosage of TGF-b2, although the
exhibited pale and patchy coloration, suggesting that lower dose caused less apparent vasoconstriction (Fig. 3B).
these organs were variably ischemic. This apparent vasoconstriction was evident throughout
Histologic evaluation of hematoxylin and eosin-stained the kidney; however, the medullary vessels were nearly
kidneys harvested from male mice treated with 100 mg/kg unperfused suggesting some regional variation. It is im-
TGF-b2 showed relatively normal renal architecture. Al- portant to note that there was no histologic evidence of
though the renal capsule had fused with the overlying a decrease in tissue vascularity. A survey of other organs
peritoneal membrane to produce a thick fibrous capsule (liver, brain, muscle, skin, spleen, adrenals, heart, and
testis) showed some effect on the myocardial vasculatureon the ventral surface, there was no histologic evidence
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Fig. 1. Kidney histopathology. (a) Control kidney cortex stained with Masson’s trichrome to illustrate the absence of fibrosis in normal tissue.
(b) TGF-b2 treated mouse kidney cortex showing patchy fibrosis confined to the tubular interstitium and vascular walls. (c) Higher magnification
of hematoxylin and eosin-stained normal glomerulus (3800) for comparison with (d ) a representative glomerulus from a TGF-b2–treated male
mouse. (e) Trichrome-stained section of normal mouse outer medulla with a longitudinal view of a single vasa recta. ( f ) Trichrome-stained section
of the outer medulla from a TGF-b2–treated mouse. Vasa recta and associated vascular supply show evidence of fibrosis with loss of vascular
space. Unless noted, all magnification is 3200. Reproduction of this figure in color was made possible by Genzyme Corporation.
and terminal branches of the hepatic artery, but these dosing with TGF-b (6 total doses) urinary TXB2 levels
measured 82 6 50 pg/mL in the treated group comparedcasts showed much less reduction in accessibility to the
casting agent than kidneys. These data clearly suggested with 22 6 17 pg/mL in the control group. At three weeks
(9 doses of TGF-b2), these values were 189 6 59 pg/mLthat TGF-b2 was promoting vascular constriction, which
if prolonged, could lead to tissue hypoxia. and 63.6 6 35 pg/mL, respectively.
The combination of elevated tissue levels of severalWe next measured endothelin-1 and angiotensin II
levels in whole kidneys in mice dosed daily for four potent vasoconstrictors in conjunction with the appear-
ance of renal vascular casts and the deposition of connec-days with 10 or 100 mg/kg TGF-b2. These results were
obtained within the same experimental group from tive tissue at tissue sites noted for susceptibility to hyp-
oxic insults prompted us to ask whether dosing withwhich the vascular casts were produced. Compared with
vehicle controls, mice dosed at 10 mg/kg had sixfold TGF-b2 caused tissue hypoxia. This hypothesis was tested
by administering pimonidazole, which when placed in ahigher levels of renal angiotensin II, and mice dosed at
100 mg/kg showed ninefold higher tissue levels of angio- net reducing environment, for example, hypoxic tissues,
forms a reactive metabolite that stably associates withtensin II (Table 1). Significant but smaller elevations in
the level of renal endothelin 1 were also recorded at both intracellular components [20]. For these experiments,
mice were treated with TGF-b2 (100 mg/kg) daily fordosage levels. These data were confirmed in a second
experiment that examined the kinetics of angiotensin II four days, and pimonidazole was administered 24 hours
after the final dose of TGF-b2. Tissues were processedand endothelin 1 production with TGF-b2 treatment at
100 mg/kg. As seen in Figure 4, levels of renal endothelin 1 for immunohistochemistry, and pimonidazole was de-
tected by reaction with a specific monoclonal antibody.were significantly elevated in the TGF-b2–treated group
after three doses of TGF-b2. Further dosing produced The cortex of normal mouse kidneys showed islands
of staining confined to the tubular interstitium but noadditional elevation in tissue levels for endothelin 1.
Significant increases in tissue levels of angiotensin II glomerular staining (Fig. 5A). Further staining was seen
in the interstitium at the cortical-medullary junction,were delayed in comparison to endothelin 1. Levels of
renal angiotensin II were unchanged after four doses of vasa recta (Fig. 5B), and loops of Henle (data not shown).
This staining pattern is consistent with published dataTGF-b2 but were significantly elevated when measured
after the sixth dose. Elevated levels of both renal vaso- that document the regions of normal kidneys with low
oxygen availability [21, 22]. In contrast, mice treated withconstrictors were reversible, declining to near control
levels within seven days of the last dose of TGF-b2. On TGF-b2 showed increased cortical staining mostly in the
tubular interstitium and associated vasculature but withthe other hand, renal fibrosis, as determined by trichrome
staining, was evident even in tissues examined four weeks little evidence of staining in the glomerulus (Fig. 5C).
Even greater staining was seen in the outer medulla andfollowing the last TGF-b2 dose. Changes in renal levels
of a third vasoconstrictor, urinary TXB2, were also mea- specifically surrounding the vasa recta (Fig. 5 D, E). The
entire inner medulla was also prominently stained (datasured in samples taken from 24-hour urine collection.
These measurements were performed with mice that had not shown).
The presence of TGF-b–mediated fibrosis at a site ofbeen dosed three times weekly with 400 mg/kg TGF-b2
also administered by intraperitoneal injection. This pro- known physiologic hypoxia suggested that other tissues
in which regional hypoxic conditions contribute to physi-tocol provided the same histopathology seen in mice
dosed daily (data not shown). Following two weeks of ologic function might also show increased connective tis-
b
Fig. 2. Procollagen III antibody staining of kidney sections prepared from control and TGF-b2 mice. Control kidney cortex (a) and outer medulla
with vasa recta (c) shows immunostaining of cortical tubular interstitium, tubular wall, vascular walls, Bowman’s capsule, and the outer renal
capsule. Kidney cortex and outer medulla prepared from a TGF-b2 mouse (b) and (d ), respectively, show intensified staining in the same locations.
No staining of the glomeruli of either control or TGF-b2–treated mice was seen with this antibody. Reproduction of this figure in color was made
possible by Genzyme Corporation.
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Fig. 4. Tissue levels of endothelin-1 (- - - -) and angiotensin II (r)
extracted from kidneys of control or TGF-b2–treated mice. Mice (N 5
8 per time point) were sacrificed and kidneys were harvested daily
beginning 24 hours after the first dose of TGF-b2 (100 mg/kg) and
continuing for a total of six doses. Two groups of mice also received
six doses, at daily intervals, but sacrifice was delayed for one and four
weeks following the final dose. A group of vehicle control mice (j)
that received six doses and were sacrificed on the seventh day served
as the baseline measurement for these proteins. *Groups achieving
statistical significance (P , 0.05).
sue deposition. Previous studies show that the liver plays
a major role in processing active, circulating TGF-b in
vivo [23], and TGF-b1 is known to induce apoptotic cell
death in cultured hepatocytes [24]. For these reasons,
the livers of mice dosed with TGF-b2 at 100 mg/kg were
examined for evidence of histopathology, and there were
two findings of note. First, there was deposition of addi-
tional extracellular matrix surrounding the central vein
(data not shown) in which the presence corresponded
to additional cells that were resident adjacent to the
central vein. Buildup of connective tissue was not seen
at other locations in the liver. Second, there was immuno-
cytochemical localization of the hypoxia imaging agent
pimonidazole, also located to the perivascular zone sur-
rounding the central vein, but it was not seen elsewhere
Fig. 3. Latex vascular casts of kidneys prepared from a control mouse
in the liver (Fig. 5 F–H).(a), a mouse treated with four daily doses of 10 mg/kg (b), or a mouse
treated with 100 mg/kg for four days (c). In the TGF-b2–treated kidneys,
there is a dose-dependent decrease in the access of the latex to the
renal vasculature, particularly in the medulla. Reproduction of this DISCUSSION
figure in color was made possible by Genzyme Corporation.
The potential breadth of clinical uses for TGF-b has
been limited by the adverse events encountered during
the initial clinical trial involving systemic administration
of TGF-b2 [17]. Patients with chronic, progressive multi-
ple sclerosis experienced a significant, but reversible, lossTable 1. Angiotensin II and endothelin-1 measurements
of glomerular filtration rate (GFR) with systemic dosingin mice kidneys
of TGF-b2. Neither the considerable body of data on theAngiotensin II Endothelin-1
biologic function of TGF-b or preclinical safety assess-
Control 0.4160.4 ng/g 169635 pg/g
ments offer a concise explanation of how TGF-b revers-TGF-b2 10 lg/kg 2.661.5 ng/g 215635 pg/ga
TGF-b2 100 lg/kg 3.661.6 ng/g 3746100 pg/ga ibly alters renal hemodynamics. In the present study, we
aP , 0.05 show that dosing normal, healthy mice with supraphysio-
Fig. 5. Localization of pimonidazole, a hypoxia-imaging agent, in tissue sections from normal and TGF-b2–treated adult male mice. (a) Kidney
cortex from a normal mouse showing patchy but specific staining of the intertubular interstitium. (b) Longitudinal section of vasa recta from a
normal mouse. (c) Staining of kidney cortex from TGF-b2-treated mouse showing enhanced and widespread staining of the intertubular interstitium
and staining of vessel walls. (d ) Longitudinal section of vasa recta from TGF-b2–treated mouse showing enhanced staining in comparison to
normal tissue. (e) Cross-section of outer medulla further demonstrating selectively enhanced staining of the vasa recta in renal tissues prepared
from a TGF-b2-treated mouse. ( f ) Section of liver from a normal mouse showing an absence of staining. (g) Liver section from a TGF-b2–treated
mouse showing selective perivascular staining surrounding the central vein. (h) Lower magnification of (g) showing selective but widespread
staining of the central vein. All magnification is at 3200 except panel h. Reproduction of this figure in color was made possible by Genzyme
Corporation.
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logic levels of active TGF-b2 rapidly results in localized bolic activity; subsequent activation of tubuloglomerular
feedback might then combine to decrease GFR. Thischanges to the structure and, indirectly, the function of
specific regions of at least two organs: kidney and liver. scenario is also consistent with our previous data in rats
demonstrating a correlation between TGF-b2–mediatedIn the kidneys of mice exposed to TGF-b2, three main
observations have been made: (1) increased production selective reduction in medullary blood flow [25] and de-
creased GFR.of potent vasoconstrictors (for example, angiotensin II
and endothelin) and reduced access of outer medullary The impact of exogenous TGF-b2, however, is not re-
stricted to the medulla since intertubular fibrosis is alsovasculature to the casting agent microfil, (2) enhancement
of regional hypoxia in the outer medulla, and (3) induc- seen in the renal cortex. Within the cortex, most of the
angiotensin II is compartmentalized in the interstitial andtion of interstitial fibrosis in the cortex and outer medulla
with a concomitant absence of glomerular fibrosis. We proximal tubular fluid [27]. The intratubular concentra-
tions of angiotensin II are in the nanomolar range, and ithave also observed that TGF-b2 causes an approximate
50% decrease in GFR in sodium/volume-depleted rats, has been suggested that angiotensin II has a role in regulat-
ing proximal tubular reabsorption rate [33] and, by exten-also in the absence of glomerulosclerosis [25].
To integrate these observations, it is important to con- sion, proximal tubular hydrostatic pressure. This effect
is biphasic, with high concentrations of angiotensin II-sider physiologic mechanisms that contribute to the regu-
lation of GFR. First, under normal physiologic conditions, inhibiting reabsorption [34]. Elevated levels of angioten-
sin II may also stimulate the production of TGF-b1 bythe outer medulla, in particular the medullary thick as-
cending limb (MTAL) and the last (S3) portion of the tubular epithelial cells [35] that could, in turn, promote
fibrosis, although TGF-b2 is also fibrogenic. In additionproximal tubule, function in a low-oxygen environment
[22]. These nephron segments are thus particularly sensi- to regulating production of extracellular matrix proteins,
TGF-b1 has also been reported to stimulate glycolysis,tive to further reductions in oxygen availability as may
be caused by vasoconstriction. Under such circumstances, reduce oxygen consumption, and significantly inhibit
Na,K-ATPase activity in cultured proximal tubule cellsthe MTAL, and to a lesser extent the proximal tubule,
can adjust to the reduced oxygen availability by reducing [36]. Whether this effect could also be achieved by exoge-
nous TGF-b2 is unknown. Although not widely appreci-normal metabolic function, for example, removal of NaCl
from tubular fluid. These changes in Cl2 concentration ated, TGF-bs have been reported to shift energy metabo-
lism toward glycolysis in several cell systems [37]. Theare monitored by the juxtaglomerular apparatus (JGA)
located at the distal end of the MTAL. In response to impact of these activities could be especially meaningful
to renal function since a shift toward aerobic glycolysisa reduction in chloride concentration in tubular fluid,
the JGA reduces glomerular blood flow by a complex might restrict ATP production, thereby reducing proxi-
mal reabsorption and the metabolic capacity of the outermechanism that is modulated by vasoactive peptides [26].
Thus, a reduction in medullary blood flow would reduce medulla. As noted earlier in this article, a reduction
of tubular reabsorption in one or both locations wouldNaCl reabsorption and thereby reduce GFR through
tubuloglomerular feedback. necessarily reduce GFR.
The effect of administering active recombinant humanWithin this context, the TGF-b2–mediated effects on
renal histopathology and tissue vasoconstrictors suggest TGF-b1 in rats and rabbits was previously reported by
Terrell et al [38]. In that study, slight glomerular hyper-several potential mechanisms by which TGF-b2 could
affect renal function. TGF-b2–mediated increases in the cellularity and tubular vacuolation were noted after 14
daily doses at levels tenfold higher than used in our study.production of renal endothelin-1 and angiotensin II would
cause a reduction in renal blood flow with a likely focus In contrast, overexpression of active TGF-b1 in the tissue
of transgenic mice causes progressive renal disease andin the medulla since both agents are at their highest con-
centration in the medulla [27, 28]. Additionally, endo- severe fibrosis [39, 40]. These mice develop widespread
glomerulosclerosis, tubular vacuolization, and interstitialthelin receptors are present at high density in the medul-
lary vasa recta [28–30]. Under normal circumstances, fibrosis that was readily observed at the magnification
provided by light microscopy. The absence of an effect onincreased vasoconstrictive activity would be balanced
through increased production of nitric oxide, a critical glomerular and tubular structures by exogenous TGF-b2
might reflect isoform specificity, issues of delivery andregulator of cortical and medullary blood flow [29, 31].
However, TGF-b potently inhibits inducible nitric oxide dosage, and the impact of high circulating TGF-b levels
during embryogenesis and tissue development.production [32]. The overall shift toward a vasoconstric-
tive effect, mediated by TGF-b2, was dramatically visual- Within the liver, the centrilobular zone normally oper-
ates at low oxygen tension by virtue of its location withinized in the latex castings of control and TGF-b2–treated
kidneys. As outlined previously in this article, a reduc- the vascular circuit. Exogenous administration of TGF-b2
increased the localization of pimonidazole adducts intion in medullary blood flow could lead to outer medul-
lary hypoxia, with concomitant decrease MTAL meta- the perivascular region of the central vein, indicating an
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exacerbation of the pre-existing hypoxia of these regions constriction-driven oxygen deficiency in the kidney leads
to regional fibrosis and altered tubular reabsorptionof the liver. Colocalization of fibrosis in these hypoxic
regions was also noted, a phenomenon seen in the kidney rates, which through tubuloglomerular feedback may
lead to compensatory reduction in GFR.in this study and reported by others in various organ
systems [41].
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